Form 4: Avidity CMO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Avidity Biosciences' Chief Medical Officer, Steven George Hughes, sold 1,542 shares of common stock for $46.66 per share, following the exercise of options, as part of a pre-arranged 10b5-1 trading plan.
Summary
- Chief Medical Officer Steven George Hughes engaged in transactions on August 13, 2025.
- Exercised options to acquire 1,542 shares of common stock at an exercise price of $6.57 per share.
- Simultaneously sold 1,542 shares of common stock at a price of $46.66 per share.
- The transactions were executed under a Rule 10b5-1 trading plan established on June 12, 2024.
- Following these transactions, beneficial ownership of common stock is 38,867 shares directly, and 50,875 shares in stock options.
Sentiment
Score: 5
Explanation: The filing reports a routine, pre-planned insider transaction (exercise and sale) under a 10b5-1 plan, which is generally considered neutral as it does not imply new discretionary insight into the company's performance.
Positives
- The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a non-discretionary sale and potentially reducing concerns about insider selling based on new, non-public information.
Negatives
- An insider sale, even if pre-planned, reduces the insider's direct equity stake in the company.
Future Outlook
NA
Industry Context
This Form 4 filing details a routine insider transaction for Avidity Biosciences, a biotechnology company. Such transactions are common across the biotech industry, particularly when executives exercise stock options and sell shares for liquidity or diversification, often under pre-arranged trading plans.
Stakeholder Impact
- Minimal direct impact on shareholders as this is a routine, pre-planned insider transaction. The sale provides liquidity to the insider but does not signal a change in company fundamentals.
Key Dates
| Date | Description |
|---|---|
| 2023-09-11 | Grant date of stock option, vesting monthly until September 11, 2027. |
| 2024-06-12 | Date Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 2025-08-13 | Transaction date for option exercise and common stock sale. |
| 2025-08-15 | Signature date of the reporting person's attorney-in-fact. |
| 2027-09-11 | Date stock option will be fully vested and exercisable. |
| 2033-09-10 | Expiration date of the stock option. |
Keywords
Avidity Biosciences, RNA, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Steven George Hughes, Chief Medical Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.